FDA Advisory Committee Recommends Approval Of Allos Therapeutics – RTT News
FDA Advisory Committee Recommends Approval Of Allos Therapeutics – RTT News
(RTTNews) – Allos Therapeutics Inc. (ALTH: News ) said Wednesday that the FDA’s Advisory Committee recommends accelerated approval of Folotyn for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. The FDA Advisory
Gloucester Gears Up for FDA Panel Vote on Lymphoma Drug – Xconomy
You can bet that the people who just put $29 million into Gloucester Pharmaceuticals a few days ago will be watching very closely today for signs they got their money’s worth. The Cambridge, MA-based biotech company will try to make its case today
FDA panel backs Allos’ lymphoma drug – Newsday
Federal health experts voted Wednesday in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration said the agency’s panel of oncology experts voted 10
FDA panel says Allos Therapeutics drug will benefit patients with rare – Los Angeles Times
WASHINGTON (AP) — Federal health experts have voted in favor of an experimental cancer drug from Allos Therapeutics for patients with a rare form of cancer. A spokeswoman for the Food and Drug Administration says the agency’s panel of cancer
